Medicament for the treatment of viral skin and tumour diseases

Details Medicament for the treatment of viral skin and tumour diseases Medicament for the treatment of viral skin and tumour diseases

2002-11-18

2010-12-28

Wang, Shengjun (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S675000, C514S560000, C514S546000, C514S934000, C514S947000, C514S967000, C514S969000, C514S453000, C514S732000

Reexamination Certificate

active

07858662

ABSTRACT:
The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21alkyl, alkylene or alkynyl group, preferably a C11-C15alkyl, alkylene or alkynyl group, particularly a C11-C13alkyl, alkylene or alkynyl group, most preferably a C13alkyl group, R2=independently, a straight or branched C1-C8alkyl, alkylene or alkynyl group, preferably a C1-C6alkyl, alkylene or alkynyl group, in particular a C2-C4alkyl, alkylene or alkynyl group, most preferably a C3alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

REFERENCES:
patent: 4002775 (1977-01-01), Kabara
patent: 4248789 (1981-02-01), Okada
patent: 4613672 (1986-09-01), Hara
patent: 4673530 (1987-06-01), Hara
patent: 4863970 (1989-09-01), Patel et al.
patent: 4913909 (1990-04-01), Hara et al.
patent: 4931284 (1990-06-01), Ekman et al.
patent: 5104901 (1992-04-01), Shimamura et al.
patent: 5135957 (1992-08-01), Shimamura
patent: 5137922 (1992-08-01), Shimamura et al.
patent: 5204089 (1993-04-01), Hara et al.
patent: 5306486 (1994-04-01), McCook et al.
patent: 5318986 (1994-06-01), Hara et al.
patent: 5358713 (1994-10-01), Shimamura
patent: 5470565 (1995-11-01), Hayakawa et al.
patent: 5633284 (1997-05-01), Meyer
patent: 5652266 (1997-07-01), Bobier-Rival et al.
patent: 5670154 (1997-09-01), Hara et al.
patent: 5747053 (1998-05-01), Nashimoto et al.
patent: 5766595 (1998-06-01), Yamane et al.
patent: 5795911 (1998-08-01), Cheng et al.
patent: 5804567 (1998-09-01), Cheng et al.
patent: 5807564 (1998-09-01), Shimamura et al.
patent: 5888527 (1999-03-01), Nashimoto et al.
patent: 5910308 (1999-06-01), D'Jang
patent: 5968973 (1999-10-01), Cheng et al.
patent: 6096359 (2000-08-01), Bombardelli et al.
patent: 6127393 (2000-10-01), Fernandez-Pol
patent: 6197808 (2001-03-01), Cheng et al.
patent: 6210679 (2001-04-01), Bailey et al.
patent: 6248346 (2001-06-01), Hara et al.
patent: 6337320 (2002-01-01), Hersh et al.
patent: 6372234 (2002-04-01), Deckers et al.
patent: 6399046 (2002-06-01), Schonrock et al.
patent: 6576660 (2003-06-01), Liao et al.
patent: 6596763 (2003-07-01), Thormar et al.
patent: 6696484 (2004-02-01), Liao et al.
patent: 6723750 (2004-04-01), Voet
patent: 2002/0006447 (2002-01-01), Yamazaki et al.
patent: 2002/0031535 (2002-03-01), Sheffield
patent: 2002/0151582 (2002-10-01), Dou et al.
patent: 2002/0198161 (2002-12-01), Brash et al.
patent: 2003/0143165 (2003-07-01), Evans et al.
patent: 2003/0166583 (2003-09-01), Yoa-Pu Hu et al.
patent: 2004/0181130 (2004-09-01), Miller et al.
patent: 2004/0191842 (2004-09-01), Hsu et al.
patent: 2005/0079235 (2005-04-01), Stockfleth
patent: 2007/0059387 (2007-03-01), Stockfleth
patent: 199 62 369 (2001-06-01), None
patent: 0 087 161 (1983-08-01), None
patent: 0 224 457 (1987-06-01), None
patent: 0 573 682 (1993-12-01), None
patent: 0 842 660 (1998-05-01), None
patent: 1 005 862 (2000-06-01), None
patent: WO 98/20872 (1998-05-01), None
patent: WO 99/66897 (1999-12-01), None
patent: WO 00/29027 (2000-05-01), None
patent: WO 00/33832 (2000-06-01), None
patent: WO 2001/051048 (2001-07-01), None
patent: WO 2004/026323 (2004-04-01), None
patent: WO 2004/053097 (2004-06-01), None
Chemical Abstracts (1974), vol. 80, No. 4, p. 319.
Garg S. et al., “Compendium of Pharmaceutical Excipients for Vaginal Formulations,”Pharmaceutical Technology Drug Deliverypp. 14-24 (2001).
CIR Compendium 1995, p. 88 (Abstract).
Beutner et al. “Treatment of Genital Warts with an Immune-Response Modifier (Imiquimod),”Journal of the American Academy of Dermatology38:230-239 (1998).
Ceve, “Drug Delivery Across the Skin,”Exp. Opin. Invest. Drugs6:1887-1937 (1997).
Diding et al., “Isopropyl Myristate as Solvent in Sterility Testing of Petrolatum-Based Ointments,” pp. 616-621 (Chemical Abstract 19503q) (1973).
Edwards et al., “Self-Administered Topical 5% Imiquimod Cream for External Anogenital Warts,”Arch. Dermatol. 134:25-30 (1998).
Kristmundsdottir et al., “Development and Evaluation of Microbicidal Hydrogels Containing Monoglyceride as the Active Ingredient,”Journal of Pharmaceutical Sciences88:1011-1015 (1999).
Sands et al., “Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols,”Antimicrobial Agents and Chemotherapy15:67-73(1979).
Handbook of Pharmaceutical Excipients, published by (1986) American Pharmaceutical Association and the Pharmaceutical Society of Great Britain pp. 148.
Beutner et al., “Patient-Applied Podofilox for Treatment of Genital Warts,”The Lancet1:831-834 (1989).
Greenberg et al., “A Double-Blind, Randomized Trial of 0.5% Podofilox and Placebo for the Treatment of Genital Warts in Women,”Obstet Gynecol. 77:735-739 (1991).
Hara, “Antioxidants in Tea and Their Physiological Functions,”Food and Free Radicals(edited by Hiramatsu et al.), Plenum Press (New York), pp. 49-65 (1997).
Kirby et al., “Double-Blind Randomized Clinical Trial of Self-Administered Podofilox Solution Versus Vehicle in the Treatment of Genital Warts,”Am J Med. 88:465-469 (1990).
Miura et al., “Effects of Various Natural Antioxidants on the Cu2+- Mediated Oxidative Modification of Low Density Lipoprotein,”Biol Pharma Bull18:1-4 (1995).
Mukoyama et al., “Inhibition of Rotavirus and Enterovirus Infections by Tea Extracts,”Jpn J Med Sci Biol. 44:181-186 (1991).
Nakayama et al., “Inhibition of the Infectivity of Influenza Virus by Tea Polyphenols,”Antivir Res. 21:289-299 (1993).
Rice-Evans et al., “The Relative Antioxidant Activities of Plant-Derived Polyphenolic Flavonoids,”Free Rad Res. 22:375-383 (1995).
Rösl et al., “Antioxidant-Induced Changes of the AP-1 Transcription Complex are Paralleled by a Selective Suppression of Human Papillomavirus Transcription,”J Virol. 71:362-370 (1997).
Toda et al., “Antibacterial and Anti-Hemolysin Activities of Tea Catechins and Their Structural Relatives,”Jpn J Bacteriol. 45:561-566 (1990). Abstract only.
Toda et al., “The Bactericidal Activity of Tea and Coffee,”Lett Appl Microbiol. 8:123-125 (1989).
Tomita et al., “Tea and Its Components as Powerful Antioxidants,”Oxidative Stress and Aging(edited by Cutler et al.), Birkhäuser Verlag (Basel, Switzerland), pp. 355-365 (1995).
Tyring et al., “Safety and Efficacy of 0.5% Podofilox Gel in the Treatment of Anogenital Warts,”Arch Dermatol. 134:33-38 (1998).
Database STN Chemical Abstracts (XP-002123681) (1995).
European Search Report for EP 08 02 1728, dated Mar. 26, 2010.
Perry et al., “Topical Imiquimod: A Review of its Use in Genital Warts, ”Drugs58(2): 375-390 (1999).
Ahmad et al., “Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells,”Journal of the National Cancer Institute89: 1881-1886 (1997).
An et al., “Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches,”Photochemistry and Photobiology76: 73-80 (2002).
Araki et al., “Chemoprevention of mammary preneoplasia. In vitro effects of a green tea polyphenol,”Annals of the New York Academy of Sciences768: 215-222 (1995).
Bickers and Athar, “Novel approac

Affiliated with

Also associated with

Rating

Medicament for the treatment of viral skin and tumour diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicament for the treatment of viral skin and tumour diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for the treatment of viral skin and tumour diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4186811